Business Context and Reporting Period
This Form 6-K filing, dated May 30, 2019, contains the CEO's message and the Notice of Convocation for the 143rd Ordinary General Meeting of Shareholders of Takeda Pharmaceutical Company Limited. The filing covers the fiscal year ended March 31, 2019 (FY2018), which includes the acquisition of Shire plc completed on January 8, 2019. The company is currently executing the integration of Shire to transform into a global, values-based, R&D-driven biopharmaceutical leader. The General Meeting is scheduled for June 27, 2019, in Yokohama, Japan.
Key Financial Metrics (FY2018)
| Metric | Value (Billion JPY) | Change vs. Prior Year |
|---|---|---|
| Revenue | 2,097.2 | +18.5% |
| Operating Profit | 205.0 | -15.2% |
| Net Profit for the Year | 109.0 | -41.6% |
| Core Earnings | 459.3 | +38.7% (Underlying) |
| Research & Development Expenses | 368.3 | +13.2% |
| Total Assets | 13,872.3 | Significant increase due to Shire acquisition |
| Total Debt (Bonds and Loans) | 3,196.4 (Bonds) / 2,554.6 (Loans) | Increased to fund Shire acquisition |
Dividend Policy: The company maintains an annual dividend of 180 JPY per share. A year-end dividend of 90 JPY per share was proposed, combined with an interim dividend of 90 JPY.
Material Changes vs. Prior Period
- Shire Acquisition Impact: The acquisition of Shire contributed 309.2 billion JPY to revenue but significantly impacted profitability due to purchase accounting effects. This included 99.2 billion JPY in amortization of intangible assets and 82.2 billion JPY in inventory fair value adjustments.
- Profitability Decline: Reported Net Profit decreased by 41.6% to 109.0 billion JPY, primarily driven by acquisition-related costs (126.3 billion JPY impact on profit before tax) and increased financial expenses (41.3 billion JPY incremental interest).
- Underlying Growth: Excluding the Shire acquisition impact, Legacy Takeda showed strong underlying performance with Revenue growth of +5.3% and Core Earnings growth of +38.7%.
- Debt Levels: Total debt increased substantially to finance the 6.2 trillion JPY Shire acquisition. The company targets a net debt/adjusted EBITDA ratio of 2x within 3 to 5 years.
Guidance, Outlook, and Risks
Management Guidance (FY2019)
- Revenue: Forecast at 3,300.0 billion JPY (+57.4% vs. prior year), reflecting full-year Shire consolidation.
- Operating Profit: Forecast at a loss of 193.0 billion JPY due to one-time integration costs (154.0 billion JPY) and purchase accounting impacts (693.0 billion JPY). Excluding these items, operating profit is expected to be 654.0 billion JPY (+38.7%).
- Core Earnings: Forecast at 883.0 billion JPY (+92.2%), with a margin improvement to 26.8%.
- Underlying Core EPS: Forecast between 350 and 370 JPY.
Strategic Priorities
- Deleveraging: Committed to reducing debt through strong cash flows and divestitures of non-core assets (e.g., Xiidra and TachoSil announced in May 2019).
- R&D Focus: Concentrating on four therapeutic areas: Oncology, Gastroenterology, Rare Diseases, and Neuroscience, plus Plasma-Derived Therapies and Vaccines.
- Integration: "Day One" integration was executed successfully; management expects minimal business disruption.
Risks and Contingencies
- Shareholder Proposals: The Board of Directors objected to two shareholder proposals: (1) Individual disclosure of directors' compensation and (2) Adoption of a clawback clause for executive compensation, citing existing robust governance and compensation policies.
- Market Risks: Exposure to pricing pressures, generic competition (e.g., VELCADE), and foreign exchange fluctuations.
Key Facts for Investor Verification
- Integration Progress: Verify the realization of cost synergies and the timeline for the "Day One" integration benefits to offset the significant one-time charges in FY2019.
- Deleveraging Strategy: Monitor the execution of the non-core asset disposal program (Xiidra, TachoSil) and the trajectory toward the 2x net debt/adjusted EBITDA target.
- Underlying Performance: Distinguish between reported GAAP results (impacted by Shire accounting) and underlying growth metrics to assess the organic health of the combined entity.
- Dividend Sustainability: Confirm the ability to maintain the 180 JPY annual dividend amidst high interest expenses and integration costs.
- R&D Pipeline: Track the progress of key pipeline assets in Oncology (NINLARO, ADCETRIS) and Rare Diseases (TAKHZYRO) which are expected to drive future growth.